Boothbay Fund Management, LLC Immuno Gen, Inc. Transaction History

Boothbay Fund Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $206,736 - $496,930	-16,592 Reduced 19.07%	70,394 $2.09 Million
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $81,228 - $114,550	-5,765 Reduced 6.22%	86,986 $1.38 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $347,816 - $1.86 Million	92,751 New	92,751 $1.75 Million
Q3 2020 Nov 16, 2020	SELL	$3.45 - $4.89 $87,664 - $124,254	-25,410 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $4,017 - $6,461	1,210 Added 5.0%	25,410 $117,000

Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $51,304 - $164,560	24,200 New	24,200 $83,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $80,130 - $122,362	-36,095 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $12,105 - $22,192	6,725 Added 22.9%	36,095 $78,000
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $70,781 - $173,576	29,370 New	29,370 $80,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.